The experimental integrase inhibitor being developed by Gilead Sciences is currently in phase III clinical trials.
The new nucleoside analogue GS-9131 may be useful as part of regimens for people who have strains of drug-resistant HIV.
A capsid inhibitor could affect three parts of HIV's life cycle and could be used by itself in the prevention of HIV infection. However, much work lies ahead before this drug's developer can be certain about that.
One study in Amsterdam deployed a strategy to identify acute HIV in men who have sex with men (MSM) and then link newly diagnosed individuals to care.
What if an electronic medical record-based algorithm could make it easier and quicker to place individuals living with hepatitis C in the care cascade? That's exactly what one study is looking into, as it aims to help identify and get individuals wit...
One study set out to evaluate the role that the microbiome plays in HIV-associated neurocognitive disorders. Terri Wilder, M.S.W., spoke with study author Josue Perez-Santiago, Ph.D., at CROI 2017.
One study set out to examine how effective opt-out testing for HIV and hepatitis C (HCV) could be among individuals who entered the Dallas County jail.
One factor that could help determine whether a person achieves an undetectable viral load is their health literacy, which is the measure of personal engagement and ability to seek medical care.
Brief, empowering messaging around pre-exposure prophylaxis (PrEP) can lead to better medication adherence, new research has found.
For one pharmacy in Seattle, the pharmacist plays multiple roles, doing everything from the HIV testing, to the patient education, to the prescribing of PrEP.